ALEC ALECTOR

Alector to Present at the Stifel 2020 Virtual Healthcare Conference

Alector to Present at the Stifel 2020 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 4:40 p.m. ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at . A replay will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit .

Contacts

Media:

Erica Jefferson

Vice President, Communications and Public Affairs

Alector, Inc.

301-928-4650

1AB

Dan Budwick

973-271-6085

or

Investors:

Alector, Inc.

EN
11/11/2020

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2025 (New York, New York) Thursday, September 4, 2025, at 3:55 p.m. ET, fireside chat Morgan Stanley 23rd Annual Global Healthcare Conference (New York, New York) Monda...

5h / 50m 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports Second Quarter 2025 Financial Results and Provides Bus...

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer’s disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investmen...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference C...

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The c...

July 31, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Provides Executive Leadership Update

Alector Provides Executive Leadership Update -- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M...

June 13, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the Goldman Sachs 46th Annual Global Healthc...

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page within the In...

June 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch